Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer

Journal of Drug Targeting

Volumn 21, Issue 10, 2013, Pages 968-980

  Peng, Zheng Hong ^a   Sima, Monika ^a   Salama, Mohamed E ^b   Kopečková, Pavla ^a   Kopeček, Jindřich ^a,c  

^a Department of Pharmaceutics and Pharmaceutical Chemistry/CCCD ^*  (United States)

^b ARUP LABORATORIES   (United States)

^c Department of Electrical and Computer Engineering   (United States)

Author keywords

C4 2; Docetaxel; DUPA; HPMA; Prostate cancer; PSMA; Targeted drug delivery

Indexed keywords

DOCETAXEL; GLUTARIC ACID; N (2 HYDROXYPROPYL)METHACRYLAMIDE; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; HISTOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROWAVE IRRADIATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; STEREOSPECIFICITY; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ACRYLAMIDES; ADENOCARCINOMA; ANIMALS; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; GLUTAMATE CARBOXYPEPTIDASE II; GLUTARATES; HUMANS; MALE; MICE; MICE, NUDE; MOLECULAR WEIGHT; OLIGOPEPTIDES; POLYMERS; PROSTATIC NEOPLASMS; TAXOIDS; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887251436     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.833207     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2013;63:11-30.
2. OlsonWC, Heston WDW, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2007;2:182-90.
3. Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin 2012;62:220-41.
4. Tannock IF, Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
5. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Disc 2008; 7:771-82.
6. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6:688-701.
7. Kopecek J. Polymer-drug conjugates: origins, progress to date and future directions. Adv Drug Delivery Rev 2013;65:49-59.
8. Kopec?ek J, Kopec?ková P. Design of polymer-drug conjugates. In: Kratz F, Senter P, Steinhagen H, eds. Drug delivery in oncology, Vol. 2, Chapter Weinheim, Germany: Wiley-VCH; 2012:485-512.
9. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012;2: 3-44.
10. Zhou Y, Kopec?ek J. Biological rationale for the design of polymeric anticancer nanomedicines. J Drug Target 2013;21:1-26.
11. Schulke N, Varlamova OA, Donovan GP, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA 2003;100:12590-5.
12. Israeli, RS, Powell CT, Corr JG, et al. Expression of the prostatespecific membrane antigen. Cancer Res 1994;54:1807-11.
13. Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528-39.
14. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003;9:6357-62.
15. Ni X, Zhang Y, Ribas J, et al. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 2011;121:2383-90.
16. Dassie JP, Liu XY, Thomas GS, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMAexpressing tumors. Nat Biotechnol 2009;27:839-46.
17. Bagalkot V, Farokhzad OC, Langer R, Jon S. An aptamerdoxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed 2006;45:8149-52.
18. Elsässer-Beile U, Reischl G, Wiehr S, et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 2009;50: 606-11.
19. Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positronemitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA 2011;108:9578-82.
20. Henry MD, Wen S, Silva MD, et al. A prostate-specific membrane antigen targeted monoclonal antibody chemotherapeutic conjugates designed for the treatment of prostate cancer. Cancer Res 2004;64: 7995-8001.
21. Moffatt S, Papasakelariou C, Wiehle S, Cristiano R. Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate. Gene Therapy 2006;13:761-72.
22. Aggarwal S, Singh P, Topaloglu O, et al. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res 2006;66:9171-7.
23. Rege K, Patel SJ, Megeed Z, Yarmush ML. Amphipathic peptidebased fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells. Cancer Res 2007;67:6368-75.
24. Kularatne SA, Wang K, Santhapuram HKR, Low PS. Prostatespecific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharmaceutics 2009;6:780-9.
25. Kularatne SA, Venkatesh C, Santhapuram HKR, et al. Synthesis and biological analysis of prostate-specific membrane antigentargeted anticancer prodrugs. J Med Chem 2010;53:7767-77.
26. Sanna V, Pintus G, Bandiera P, et al. Development of polymeric microbubbles targeted to prostate-specific membrane antigen as prototype of novel untrasound contrast agents. Mol Pharmaceutics 2011;8:748-57.
27. Banerjee SR, Pullambhatla M, Byun Y, et al. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed 2011;50:9167-70.
28. Humblet V, Misra P, Bhushan KR, et al. Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. J Med Chem 2009;52: 544-50.
29. Maresca KP, Hillier SM, Femia FJ, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 2009;52:347-57.
30. Liu T, Nedrow-Byers JR, Hopkins MR, Berkman CE. Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitor of prostate specific membrane antigen. Bioorg Med Chem 2011;21:7013-16.
31. Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Disc 2005;4:1015-25.
32. Jayaprakash S, Wang X, Heston WD, Kozikowski AP. Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. ChemMedChem 2006;1:299-302.
33. Zhang AX, Murelli RP, Barinka C, et al. A remote arene-binding site on prostate specific membrane antigen revealed by antibodyrecruiting small molecules. J Am Chem Soc 2010;132:12711-16.
34. Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci USA 2005;102:5981-6.
35. Mesters JR, Barinka C, Li W, et al. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 2006;25:1375-84.
36. Kopec?ek J, Kopec?ková, P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Delivery Rev 2010; 62:122-49.
37. Kopec?ek J, Baz?ilová H. Poly[N-(2-hydroxypropyl)methacrylamide]. Radical polymerization and copolymerization. Eur Polym J 1973;9:7-14.
38. Rejmanová P, Pohl J, Baudys? M, et al. Polymers containing enzymatically degradable bonds. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol Chem 1983;184:2009-20.
39. Mitsukami Y, Donovan MS, Lowe AB, McCormick CL. Watersoluble polymers. Direct synthesis of hydrophilic styrenic-based homopolymers and block copolymers in aqueous solution via RAFT. Macromolecules 2001;34:2248-56.
40. Satchi-Fainaro R, Puder M, Davies JW, et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004;10:255-61.
41. Liu J, Kopec?ková, P, Pan H, et al. Prostate cancer targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates. Macromol Biosci 2012;12:412-22.
42. York AW, Kirkland SE, McCormick CL. Advances in the synthesis of amphiphilic block copolymers via RAFT polymerization: stimuli-responsive drug and gene delivery. Adv Drug Delivery Rev 2008;60:1018-36.
43. Etrych T, S ? ?́rová M, Starovoytova L, et al. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release. Mol Pharmaceutics 2010;7:1015-26.
44. Thaimann GN, Anezinis PE, Chang SM, et al. Androgenindependent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54: 2577-81.